Is the price fair?
What RGEN's price assumes
Repligen Corporation trades at 247× earnings against 42.5× for the median Medical Instruments & Supplies name, more expensive than its own group.
247
Trailing P/E · Medical Instruments & Supplies median 42.5 · 5.81× the median: the market pays up for this one
- Price / sales
- 8.75
Price / sales · as of 2026-Q1
- Free cash flow yield
- 1.5%
Free cash flow yield · Medical Instruments & Supplies median 3.7%
- Growth the price implies
- +22%
Growth the price implies · The price pays for +22% free cash flow growth a year for a decade; the business has delivered +3.9% a year over the last three.
Details›
- Price / book2026-Q1
- 3.17
- EV / EBIT2026-Q1
- 103
- EV / sales2026-Q1
- 8.70
- Healthcare median P/E362 names
- 31.5
- Medical Instruments & Supplies median P/E29 names
- 42.5
- Free cash flow, trailing twelve months
- $112M
- Market capitalisation
- $7.45B
- 3-year revenue growth
- +3.3%
- 3-year free cash flow growth
- +3.9%
| Method | Per share |
|---|---|
| Its own P/E history, lower quartile | $54.56 |
| Its own P/E history, median | $80.79 |
| Its own P/E history, upper quartile | $107.74 |
| 52-week range | $102.87 – $181.76 |
| Today | $180.23 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Medical Instruments & Supplies
Ranks #11 of 27 by Smart Score